References
- Rowinsky EK, Donehower RC. Paclitaxel. N Engl J Med 1995;332:1004–14
- Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995;13:2643–55
- Cormio G, Di Vagno G, Melilli GA, et al. Hypersensitivity reactions in ovarian cancer patients receiving paclitaxel. J Chemother 1999;11:407–9
- Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990;8:1263–8
- Verweij J, Clavel M, Chevalier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol 1994;5:495–505
- Dye D, Watkins J. Suspected anaphylactic reaction to Cremophor EL. Br Med J 1980;280:1353
- Hoetelmans RM, Schornagel JH, ten Bokkel Huinink WW, et al. Hypersensitivity reactions to etoposide. Ann Pharmacother 1996;30:367–71
- Carter JJ, McLaughlin ML, Bern MM. Bleomycin-induced fatal hyperpyrexia. Am J Med 1983;74:523–5
- Levy RL, Chiarillo S. Hyperpyrexia, allergic-type response and death occurring with low-dose bleomycin administration. Oncology 1980;37:316–7
- Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 2003;24:253–62
- Evans WE, Tsiatis A, Rivera G, et al. Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer 1982;49:1378–83
- Price KS; Castells MC. Taxol reactions. Allergy Asthma Proc 2002;23:205–8
- Krieger JA, Stanford BL, Ballard EE, et al. Implementation and results of a test dose program with taxanes. Cancer J 2002;8:337–41
- National Cancer Institute Common Toxicity Criteria Version 2.0, 1999 [online]. Available from http://ctep.cancer.gov/forms/ctcaev2to3.pdf [last accessed 15 June 2005]
- Anon. Drug topics redbook. Montvale (NJ): Medical Economics; 2004